Suppressing effects of dietary supplementation of soybean trypsin inhibitor on spontaneous, experimental and peritoneal disseminated metastasis in mouse model

International Journal of Cancer

Volumn 112, Issue 3, 2004, Pages 519-524

  Kobayashi, Hiroshi ^a   Fukuda, Yoichi ^b   Yoshida, Ryuji ^b   Kanada, Yasufumi ^b   Nishiyama, Setsuko ^b   Suzuki, Mika ^a   Kanayama, Naohiro ^a   Terao, Toshihiko ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b FUJI OIL CO LTD   (Japan)

Author keywords

Dietary supplementation; Metastasis; Soybean; Trypsin inhibitor; Urokinase

Indexed keywords

APROTININ; BOWMAN BIRK INHIBITOR; GRANULOCYTE COLONY STIMULATING FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE; SOYBEAN TRYPSIN INHIBITOR; TRANSFORMING GROWTH FACTOR BETA1; UROKINASE;

ANIMAL CELL; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOSE RESPONSE; DRUG EFFECT; FEMALE; IMMUNOBLOTTING; LUNG METASTASIS; LUNG TUMOR; METASTASIS; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; STATISTICAL SIGNIFICANCE; TUMOR CELL;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; CARCINOMA, LEWIS LUNG; CELL LINE, TUMOR; DIETARY SUPPLEMENTS; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LUNG NEOPLASMS; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED C57BL; MODELS, ANIMAL; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PHOSPHORYLATION; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TRYPSIN INHIBITOR, BOWMAN-BIRK SOYBEAN; TRYPSIN INHIBITOR, KUNITZ SOYBEAN; TRYPSIN INHIBITORS; URINARY PLASMINOGEN ACTIVATOR;

EID: 6344290025     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20430     Document Type: Article

References (31)

1. Sidenius N, Blasi F. The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev 2003;22:205-22.
2. Ossowski L. In vivo invasion of modified chorioallantoic membrane by tumor cells: the role of cell surface-bound urokinase. J Cell Biol 1988;107:2437-45.
3. Nyberg P, Moilanen M, Paju A, Sarin A, Stenman UH, Sorsa T, Salo T. MMP-9 activation by tumor trypsin-2 enhances in vivo invasion of human tongue carcinoma cells. J Dent Res 2002;81:831-5.
4. Tsuboi R, Rifkin DB. Bimodal relationship between invasion of the amniotic membrane and plasminogen activator activity. Int J Cancer 1990;46:56-60.
5. Rao JS, Steck PA, Tofilon P, Boyd D, Ali-Osman F, Stetler-Stevenson WG, Liotta LA, Sawaya R. Role of plasminogen activator and of 92-KDa type IV collagenase in glioblastoma invasion using an in vitro matrigel model. J Neurooncol 1994;18:129-38.
6. Mignatti P, Rifkin DB. Plasminogen activators and matrix metalloproteinases in angiogenesis. Enzyme Protein 1996;49:117-37.
7. Mueller BM. Different roles for plasminogen activators and metalloproteinases in melanoma metastasis. Curr Top Microbiol Immunol 1996;213:65-80.
8. Kobayashi H, Suzuki M, Hirashima Y, Terao T. The protease inhibitor bikunin, a novel anti-metastatic agent. Biol Chem 2003;384:749-54.
9. Kobayashi H, Suzuki M, Kanayama N, Terao T. A soybean Kunitz trypsin inhibitor suppresses ovarian cancer cell invasion by blocking urokinase upregulation. Clin Exp Metastasis, 2004;21:159-66.
10. Pusztai A, Watt WB, Stewart JC. A comprehensive scheme for the isolation of trypsin inhibitors and the agglutinin from soybean seeds. J Agric Food Chem 1991;39:882-6.
11. Kobayashi H, Gotoh J, Shinohara H, Moniwa N, Terao T. Inhibition of the metastasis of Lewis lung carcinoma by antibody against urokinase-type plasminogen activator in the experimental and spontaneous metastasis model. Thromb Haemost 1994;71:474-80.
12. Suzuki M, Kobayashi H, Tanaka Y, Hirashima Y, Kanayama N, Takei Y, Saga Y, Suzuki M, Itoh H, Terao T. Suppression of invasion and peritoneal carcinomatosis of ovarian cancer cell line by overexpression of bikunin. Int J Cancer 2003;104:289-302.
13. Kobayashi H, Shinohara H, Fujie M, Gotoh J, Itoh M, Takeuchi K, Terao T. Inhibition of metastasis of Lewis lung carcinoma by urinary trypsin inhibitor in experimental and spontaneous metastasis models. Int J Cancer 1995;63:455-62.
14. Brodt P, Reich R, Moroz LA, Chambers AF. Differences in the repertoires of basement membrane degrading enzymes in two carcinoma sublines with distinct patterns of site-selective metastasis. Biochim Biophys Acta 1992;1139:77-83.
15. Pei XH, Nakanishi Y, Takayama K, Bai F, Kawasaki M, Hara N. G-CSF increases secretion of urokinase-type plasminogen activator by human lung cancer cells. Clin Exp Metastasis 1998;16:551-8.
16. Ostrowski LE, Ahsan A, Suthar BP, Pagast P, Bain DL, Wong C, Patel A, Schultz RM. Selective inhibition of proteolytic enzymes in an in vivo mouse model for experimental metastasis. Cancer Res 1986; 46:4121-8.
17. Ossowski L, Reich E. Antibodies to plasminogen activator inhibit human tumor metastasis. Cell 1983;35:611-9.
18. Kobayashi H, Suzuki M, Tanaka Y, Kanayama N, Terao T. A Kunitz-type protease inhibitor, bikunin, inhibits ovarian cancer cell invasion by blocking the calcium-dependent transforming growth factor-beta 1 signaling cascade. J Biol Chem 2003;278:7790-9.
19. Suzuki M, Kobayashi H, Tanaka Y, Hirashima Y, Terao T. Structure and function analysis of urinary trypsin inhibitor (UTI): identification of binding domains and signaling property of UTI by analysis of truncated proteins. Biochim Biophys Acta 2001;1547:26-36.
20. Kobayashi H, Suzuki M, Tanaka Y, Hirashima Y, Terao T. Suppression of urokinase expression and invasiveness by urinary trypsin inhibitor is mediated through inhibition of protein kinase C- and MEK/ERK/c-Jun-dependent signaling pathways. J Biol Chem 2001;276:2015-22.
21. Kobayashi H, Gotoh J, Terao T. Urinary trypsin inhibitor efficiently inhibits urokinase production in tumor necrosis factor-stimulated cells. Eur J Cell Biol 1996;71:380-6.
22. Kobayashi H, Sugino D, Terao T. Urinary trypsin inhibitor, a Kunitz-type protease inhibitor, modulates tumor necrosis factor-stimulated activation and translocation of protein kinase C in U937 cells. Int J Oncol 1998;12:95-105.
23. Kobayashi H, Yagyu T, Inagaki K, Kondo T, Suzuki M, Kanayama N, Terao T. Therapeutic efficacy of once-daily oral administration of a Kunitz-type protease inhibitor, bikunin, in a mouse model and in human cancer. Cancer 2004;100:869-77.
24. Miyagi Y, Shinjo S, Nishida R, Miyagi C, Takamatsu K, Yamamoto T, Yamamoto S. Trypsin inhibitor activity in commercial soybean products in Japan. J Nutr Sci Vitaminol (Tokyo) 1997;43:575-80.
25. Lu LJ, Anderson KE, Grady JJ, Nagamani M. Effects of an isoflavone-free soy diet on ovarian hormones in premenopausal women. J Clin Endocrinol Metab 2001;86:3045-52.
26. von Hofe E, Newberne PM, Kennedy AR. Inhibition of N-nitro- somethylbenzylamine-induced esophageal neoplasms by the Bowman-Birk protease inhibitor. Carcinogenesis 1991;12:2147-50.
27. Azuma N, Machida K, Saeki T, Kanamoto R, Iwami K. Preventive effect of soybean resistant proteins against experimental tumorigenesis in rat colon. J Nutr Sci Vitaminol (Tokyo) 2000;46:23-9.
28. Tolcher AW, Kennedy A, Padley RJ, Majeed N, Pollak M, Kantoff PW. Other novel agents: rationale and current status as chemopreventive agents. Urology 2001;57:86-9.
29. Corpet DE, Tache S. Most effective colon cancer chemopreventive agents in rats: a systematic review of aberrant crypt foci and tumor data, ranked by potency. Nutr Cancer 2002;43:1-21.
30. Kennedy AR, Billings PC, Wan XS, Newberne PM. Effects of Bowman-Birk inhibitor on rat colon carcinogenesis. Nutr Cancer 2002;43:174-86.
31. Malkowicz SB, Liu SP, Broderick GA, Wein AJ, Kennedy AR, Levin RM. Effect of the Bowman-Birk inhibitor (a soy protein) on in vitro bladder neck/urethral and penile corporal smooth muscle activity. Neurourol Urodyn 2003;22:54-7.